[go: up one dir, main page]

NO20053246L - Kondensert 1,3-dihydroimidazol-ringforbindelse. - Google Patents

Kondensert 1,3-dihydroimidazol-ringforbindelse.

Info

Publication number
NO20053246L
NO20053246L NO20053246A NO20053246A NO20053246L NO 20053246 L NO20053246 L NO 20053246L NO 20053246 A NO20053246 A NO 20053246A NO 20053246 A NO20053246 A NO 20053246A NO 20053246 L NO20053246 L NO 20053246L
Authority
NO
Norway
Prior art keywords
condensed
ring compound
optionally substituted
dihydroimidazole ring
nitrogen
Prior art date
Application number
NO20053246A
Other languages
English (en)
Other versions
NO20053246D0 (no
Inventor
Richard Clark
Seiji Yoshikawa
Kazunobu Kira
Taisuke Uehara
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of NO20053246D0 publication Critical patent/NO20053246D0/no
Publication of NO20053246L publication Critical patent/NO20053246L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)

Abstract

En ny forbindelse med glimrende DPPIV-inhiberende aktivitet. Den er en forbindelse representert ved generell formel (I) (I) (hvor T1 betyr en eventuelt substituert, mono- eller bisyklisk, 4- til 12-leddet heterosyklus inneholdende 1 eller 2 nitrogenatomer, hvor strukturen vist ved (II) (II) betyr en dobbeltbinding eller enkelt-binding; X3 betegner oksygen eller svovel, X1 betegner eventuelt substituert C2-6~alkynyl, etc; Z1 betegner nitrogen eller -CR3=; Z2 og Z3 betegner hver uavhengig nitrogen, -CR1=, karbonyl eller -NR2-; og R1, R2, R3 og X2 betegner hver uavhengig eventuelt substituert Ci-6-alkyl, etc), eller et salt derav eller et hydrat derav.
NO20053246A 2002-12-04 2005-07-01 Kondensert 1,3-dihydroimidazol-ringforbindelse. NO20053246L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002352186 2002-12-04
PCT/JP2003/015402 WO2004050656A1 (ja) 2002-12-04 2003-12-02 １，３−ジヒドロ−イミダゾール縮合環化合物

Publications (2)

Publication Number Publication Date
NO20053246D0 NO20053246D0 (no) 2005-07-01
NO20053246L true NO20053246L (no) 2005-08-30

Family

ID=32463216

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053246A NO20053246L (no) 2002-12-04 2005-07-01 Kondensert 1,3-dihydroimidazol-ringforbindelse.

Country Status (16)

Country Link
US (1) US7524847B2 (no)
EP (1) EP1568699A4 (no)
JP (1) JP4279784B2 (no)
KR (1) KR100867484B1 (no)
CN (1) CN100376573C (no)
AU (1) AU2003302657B8 (no)
BR (1) BR0316991A (no)
CA (1) CA2507763A1 (no)
IL (1) IL168784A (no)
MX (1) MXPA05005983A (no)
NO (1) NO20053246L (no)
NZ (1) NZ540495A (no)
PL (1) PL377187A1 (no)
RU (1) RU2328498C9 (no)
WO (1) WO2004050656A1 (no)
ZA (1) ZA200504973B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074798B2 (en) 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
CN100348599C (zh) 2002-06-06 2007-11-14 卫材R&D管理有限公司 新的稠合咪唑衍生物
US20040242566A1 (en) 2003-03-25 2004-12-02 Syrrx, Inc. Dipeptidyl peptidase inhibitors
JP2007511467A (ja) 2003-05-14 2007-05-10 タケダ サン ディエゴ インコーポレイテッド ジペプチジルペプチダーゼインヒビター
MXPA06001601A (es) 2003-08-13 2006-08-25 Takeda Pharmaceutical Derivados de 4-pirimidona y su uso como inhibidores de dipeptidilpeptidasa.
WO2005118555A1 (en) * 2004-06-04 2005-12-15 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
SI1942898T2 (sl) 2005-09-14 2014-08-29 Takeda Pharmaceutical Company Limited Dipeptidil-peptidazni inhibitorji za zdravljenje diabetesa
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP2013206A1 (en) * 2006-04-25 2009-01-14 Astex Therapeutics Limited Pharmaceutical compounds
EP2043655A2 (en) 2006-04-25 2009-04-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
JP4705695B2 (ja) 2007-10-11 2011-06-22 アストラゼネカ アクチボラグ プロテインキナーゼｂ阻害剤としてのピロロ［２，３−ｄ］ピリミジン誘導体
CN102171210B (zh) * 2008-08-05 2014-04-23 第一三共株式会社 咪唑并吡啶-2-酮衍生物
CA2754890C (en) * 2009-03-13 2018-01-16 Piet Herdewijn Bicyclic heterocycles
CN102127070A (zh) 2010-01-15 2011-07-20 山东轩竹医药科技有限公司 吡啶并环衍生物
CN102153538B (zh) * 2010-02-11 2013-12-11 山东轩竹医药科技有限公司 苯并环衍生物
CN102276627B (zh) * 2010-04-29 2013-07-31 山东轩竹医药科技有限公司 吡啶并杂环衍生物
CN102234281B (zh) * 2010-04-29 2013-03-27 山东轩竹医药科技有限公司 嘧啶并环衍生物
JP6080837B2 (ja) 2011-04-01 2017-02-15 アストラゼネカ アクチボラグ 療法的治療
JP5695800B2 (ja) * 2011-07-09 2015-04-08 山東軒竹医薬科技有限公司 ジペプチジルペプチダーゼ−ｉｖ阻害剤の塩の結晶形ｉ、及びその製造方法並びにその応用
KR102035361B1 (ko) 2011-11-30 2019-11-08 아스트라제네카 아베 암의 병용 치료
US8501724B1 (en) * 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
WO2015078799A1 (en) * 2013-11-27 2015-06-04 Bayer Pharma Aktiengesellschaft Glucose transport inhibitors
CN110872297B (zh) * 2018-09-04 2023-02-14 上海再极医药科技有限公司 氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CN109608462B (zh) * 2018-12-15 2021-11-23 华南理工大学 一种7-烃基-9-烷氧/硫基嘌呤-8-酮类化合物及其合成方法与在药物中的应用
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8515934D0 (en) * 1985-06-24 1985-07-24 Janssen Pharmaceutica Nv (4-piperidinomethyl and-hetero)purines
US5057517A (en) * 1987-07-20 1991-10-15 Merck & Co., Inc. Piperazinyl derivatives of purines and isosteres thereof as hypoglycemic agents
NZ225447A (en) * 1987-07-20 1991-12-23 Merck & Co Inc Piperazinyl derivatives of purine and purine isosteres and pharmaceutical compositions
JP2000086663A (ja) * 1998-09-09 2000-03-28 Taisho Pharmaceut Co Ltd アリールテトラヒドロピリジン誘導体
US6600038B1 (en) 1999-03-11 2003-07-29 Taisho Pharmaceutical Co., Ltd. Carbamoyl tetrahydropyridine derivatives
JP2001151777A (ja) 1999-03-11 2001-06-05 Taisho Pharmaceut Co Ltd カルバモイルテトラヒドロピリジン誘導体
US7074798B2 (en) * 2002-02-25 2006-07-11 Eisai Co., Ltd Xanthine derivative and DPPIV inhibitor
CN100348599C (zh) * 2002-06-06 2007-11-14 卫材R&D管理有限公司 新的稠合咪唑衍生物
US20060094722A1 (en) 2002-09-26 2006-05-04 Eisai Co., Ltd. Combination drug
US7122665B2 (en) * 2002-10-15 2006-10-17 Synta Pharmaceuticals Corp. Heterocyclic compounds
WO2005044793A2 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
KR101099206B1 (ko) * 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제

Also Published As

Publication number Publication date
US7524847B2 (en) 2009-04-28
RU2328498C2 (ru) 2008-07-10
US20060111362A1 (en) 2006-05-25
EP1568699A1 (en) 2005-08-31
AU2003302657A2 (en) 2004-06-23
HK1086556A1 (zh) 2006-09-22
CN1745080A (zh) 2006-03-08
NZ540495A (en) 2007-09-28
MXPA05005983A (es) 2005-08-18
JP4279784B2 (ja) 2009-06-17
JPWO2004050656A1 (ja) 2006-03-30
WO2004050656A1 (ja) 2004-06-17
PL377187A1 (pl) 2006-01-23
AU2003302657A1 (en) 2004-06-23
BR0316991A (pt) 2005-10-25
AU2003302657B8 (en) 2009-12-03
RU2005120780A (ru) 2006-01-20
KR100867484B1 (ko) 2008-11-06
EP1568699A4 (en) 2007-08-15
RU2328498C9 (ru) 2008-12-10
IL168784A (en) 2010-12-30
CN100376573C (zh) 2008-03-26
ZA200504973B (en) 2006-04-26
KR20050087825A (ko) 2005-08-31
AU2003302657B2 (en) 2009-09-24
NO20053246D0 (no) 2005-07-01
CA2507763A1 (en) 2004-06-17

Similar Documents

Publication Publication Date Title
NO20053246L (no) Kondensert 1,3-dihydroimidazol-ringforbindelse.
NL300927I1 (nl) tivozanib of een zout of hydraat ervan, in het bijzonder het hydrochloride-monohydraat
DE60322224D1 (de) Kondensierte heterozyklische verbindungen als petidase inhibitoren
AP1902A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
NO20033848L (no) Nitrogenholdige heteroarylforbindelser med en HIV integrase inhiberende aktivitet
BRPI0211844B8 (pt) composto de ácido fenóxi-acético ou um de seus sais farmaceuticamente aceitáveis, e, composição farmacêutica
CY1113782T1 (el) Παραγωγα 11-υδροξυ-5η-πυρρολο[2,1-c][1,4]βενζοδιαζεπιν-5-ονης ως ενδιαμεσα κλειδια για την παρασκευη c2 υποκατεστημενων πυρρολοβενζοδιαζεπινων
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
ES2166359T3 (es) Derivado de depsipeptido, su produccion y uso.
GB0123589D0 (en) Organic compounds
ATE338461T1 (de) Pyrazolpyrimidinfungizide
TW200602322A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
EP1724258A4 (en) HETEROARYLPHENYLUREE DERIVATIVE
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
ID25649A (id) Turunan-turunan sikloalkena, produksi serta penggunaannya
WO2004031145A3 (en) Lactam-containing diaminoalkyl, beta-aminoacids, alpha-aminoacids and derivatives thereof as factor xa inhibitors
ATE305777T1 (de) Mittel zur verhinderung der chronischen abstossreaktion infolge einer organtransplantation
DK1447400T3 (da) Bicyklisk forbindelse
ID24846A (id) Turunan-turunan bifenilamidina
MY140749A (en) Novel piperidine compound
DE60002558D1 (de) Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B
DK1554285T3 (da) Kemisk mellemprodukt
DE60225019D1 (de) Nicht-nucleosidische inhibitoren der reverse transkriptase
ATE420068T1 (de) Reverse hydroxamsäurederivate
BR0307424A (pt) Compostos heterocìclicos com atividade inibidora de elastase e seus intermediários

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application